Current COVID-19 vaccines are not well-matched against the BA.2 sub-variant of Omicron, the U.S. Food and Drug Administration said on April 6, as its panel of outside experts meets to discuss changes to future booster doses.
A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study in Israel found.
U.S. FDA Advisers to Discuss Additional COVID Vaccine Boosters
BNT162b2 (Pfizer and BioNTech), Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Reinfections, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, FDA, FDA Statements, FDA/Regulatory, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Research & Development, Therapeutics, VaccinesThe U.S. Food and Drug Administration’s expert advisers will discuss the timing of additional COVID-19 vaccine boosters and the people eligible for the extra shots in a meeting later this week, the health agency said on April 4.
Children ages 5 to 11 who received the Pfizer/BioNTech COVID-19 vaccine were 68% less likely to be hospitalized during the Omicron wave in the United States than unvaccinated children, according to a study published on March 30.
White House launches COVID.gov amid push for more funds, booster shots
BNT162b2 (Pfizer and BioNTech), Congress, Coronavirus Cases, COVID-19 booster shots, COVID-19 Vaccines, Democrats, Funding, Health Officials, Immunocompromised, Joe Biden, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Websites, White HouseThe Biden administration on Wednesday launched a new website to provide a clearinghouse of information on COVID-19 as part of a continuing effort to prepare Americans to live with the coronavirus.
The U.S. Food and Drug Administration will weigh the benefits of authorizing a round of boosters of either the Pfizer/BioNTech or Moderna COVID-19 vaccine to a broader population in the fall, a top official said on March 29.
Without holding a meeting of its vaccines advisory committee, the U.S. Food and Drug Administration (FDA) authorized a fourth shot of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 50 years of age and older.
Second COVID vaccine booster significantly lowers death rate, Israeli study shows
BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, COVID-19 booster shots, COVID-19 Mortality, COVID-19 Studies, COVID-19 Vaccines, Death Rates, Elderly, Israel, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), R&DSenior citizens who received a second booster of the Pfizer-BioNTech COVID-19 vaccination had a 78 percent lower mortality rate from the disease than those who got one only, a study from Israel showed on March 27.
With Robust Results, Moderna to Request Vaccine EUA for Kids Under 6
BNT162b2 (Pfizer and BioNTech), CDC, Children, Clinical Trials, COVID-19 Vaccines, Data, Emergency Use Authorization (EUA), Immunogenicity Data, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&DModerna reported positive interim results from the Phase II/III KidCOVE trial of the company’s mRNA COVID-19 vaccine for children six months to under two years and also two to six years of age.
U.S. FDA advisers to discuss COVID vaccine boosters in April
BNT162b2 (Pfizer and BioNTech), Center for Biologics Evaluation and Research (CBER), COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, FDA/Regulatory, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Vaccines and Related Biological Products Advisory CommitteeThe U.S. drug regulator said on March 21 a panel of independent advisers will meet on April 6 to discuss considerations for use of COVID-19 vaccine booster doses.